Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8221 results

  1. Cosibelimab for treating advanced cutaneous squamous cell carcinoma when curative surgery or radiotherapy is unsuitable [ID6663]

    Awaiting development Reference number: GID-TA11883 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management

    In development Reference number: GID-NG10435 Expected publication date: TBC

    NICE guideline
    In development

  3. Ex-situ machine perfusion devices for deceased donor liver transplants

    In development Reference number: GID-HTE10066 Expected publication date:  20 August 2026

    Health technology evaluations
    In development

  4. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Type 2 diabetes in adults: management (medicines update)

    In development Reference number: GID-NG10336 Expected publication date:  18 February 2026

    NICE guideline
    In development

  6. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Ensitrelvir for treating COVID-19 [ID6231]

    In development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

    Awaiting development Reference number: GID-TA10777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vamikibart for treating uveitic macular oedema [ID6671]

    Awaiting development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  12. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC

    Health technology evaluations
    In development

  13. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

    In development Reference number: GID-TA11422 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

    In development Reference number: GID-TA11675 Expected publication date: TBC

    Technology appraisal guidance
    In development